Product information and disease descriptionPlace of product in therapyDisease description
Pathophysiology
18 evidence topics · 10 sources
Estrogen receptor expression and dependence on estrogen receptor signaling
“Upon activation by oestrogen, ER executes a transcriptional programme that drives proliferation and expansion of the mammary epithelia during puberty” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“~70–80% of tumours that emerge from the mammary gland express ER and harbour some dependence on ER signalling for proliferation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although most ER+ tumours initially appear sensitive to anti-oestrogen agents, resistance can develop over time, characterized by clinical relapse, which typically involves the emergence of genetic and epigenetic alterations that allow for reactivation of ER signalling” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ligand-dependent estrogen receptor activation
Activation function domains AF-1 and AF-2
“ER consists of two transcriptional activation domains, the N-terminal ligand-independent activation function (AF)-1 and the C-terminal ligand-dependent AF-2 domains, a ligand-binding domain (LBD) also residing in the C-terminal region, and the DNA-binding and hinge domains, positioned in the core of the protein.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AF-1 activity and incomplete antagonism by selective estrogen receptor modulators
“SERMs still allow for the engagement of ER with chromatin and therefore do not inhibit transcription driven by the N-terminal ER activation function-1 (AF1) domain” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As AF1 activity is sensitive to various cellular inputs, the impact of SERMs on ER transcriptional output depends on the tissue environment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Selective ER degraders inhibit both LBD and AF1 domains by preventing recruitment of co-activators, immobilizing and destabilizing ER, leading to degradation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ESR1 ligand-binding domain mutations in the AF-2 region
“All ESR1 mutations were located within the LBD/activation function-2 (AF-2) domain of the receptor and the majority occurred specifically at amino acids 537 and 538 of helix 12” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consistent with this model, mutant receptors drive ER-dependent transcription and proliferation in the absence of hormone and reduce the efficacy of ER antagonists.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Constitutive activity and reduced drug binding of mutant estrogen receptor
“Whereas wild-type ESR1 (ESR1-WT) is bound by estrogen ligand to enable coactivator recruitment, LBD-mutated ESR1 (ESR1-MUT) is constitutively active and thus unaffected by AI depletion of estrogen” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For tamoxifen, ESR1-MUT has up to 30-fold decreased binding affinity (varying by specific mutation) and requires higher doses to inhibit transactivation function and cell proliferation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For fulvestrant, ESR1-MUT has up to 40-fold decreased binding affinity and, like tamoxifen, requires an increased dose by an order of magnitude to inhibit transactivation function and cell expansion in culture and xenograft models” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ESR1 mutations acquired under aromatase inhibitor therapy for metastatic disease
“ESR1 mutations were found exclusively in patients with estrogen receptor positive breast cancer previously exposed to AI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ESR1 mutation prevalence differed markedly between patients that were first exposed to AI during the adjuvant and metastatic settings (5.8% (3/52) vs 36.4% (16/44) respectively, p=0.0002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ESR1 mutations are rarely acquired during adjuvant AI therapy, but are commonly selected by therapy for metastatic disease” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of ESR1 mutations by prior endocrine therapy setting
“The prevalence of ESR1 mutations in patients depends on prior duration and setting of endocrine therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 20–40% of patients who have received aromatase inhibition (AI) for MBC have ESR1 mutations, with prevalence varying by sites of metastatic disease” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, ESR1 mutations in HR-positive breast cancer occur almost exclusively after AI in the metastatic setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of ESR1 mutations in plasma after aromatase inhibitor exposure in BOLERO-2
Prevalence of ESR1 mutations by line of therapy in real-world genomic testing
“ESR1mut was found in 8.1% TBx, 17.5% LBx TF ≥ 1%, and 4.9% LBx TF < 1% in 1st line, increasing to 59% in 3rd line (LBx TF ≥ 1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the prevalence of ESR1mut in TBx collected within 60 days before or after the initiation of 1st, 2nd, and 3rd lines of therapy was 8.1% (n = 175/2,154), 27.1% (n = 73/269), and 33.3% (n = 72/216), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of ESR1 mutations before and after endocrine therapy
ESR1 mutation as one of several endocrine resistance mechanisms
“About 50% of endocrine resistance cases are associated with an ESR1 mutation; other mechanisms, increasingly uncovered, include alterations in the PI3K-AKT-mTORC1, RAS-MAPK, and CDK4/6-RB-E2F pathways, and ESR1 loss, amplification, and translocation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ESR1 fusions are rare but exhibit complete resistance to treatments targeting the LBD of ESR1 such as selective estrogen receptor modulators (SERMs) and degraders (SERDs), as these fusions lack the LBD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ligand-independent estrogen receptor reactivation through growth factor signaling
“Instead, endocrine resistance is commonly driven by ligand-independent ER reactivation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Upon adaptation and/or resistance to antiestrogens, growth factor-driven mitogenic and survival pathways (i.e., PI3K/mTOR, RAS/RAF/MEK/ERK) can drive reactivation of ER transcription in the absence of estradiol.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These resistant tumors are typically dependent upon both the aberrantly activated survival pathway and ER, and in most cases combined inhibition of both pathways is more effective” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PI3K, AKT, and PTEN pathway alterations
“Components of the PI3K pathway (including PIK3CA, PTEN, and AKT1) are frequently mutated in ER+ breast cancers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Aberrant activation of the PI3K pathway promotes acquired resistance to estrogen depletion in preclinical models” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AKT1 and PTEN mutations are more frequent in advanced/metastatic ER+ breast cancers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of PI3K, AKT, and PTEN alterations by line of therapy
“1002 (17.3%) TBx and 503 (30.1%) LBx had an ESR1mut detected; 2,442 (42.2%) TBx and 564 (33.8%) LBx had a PIK3CAmut detected; 289 (5%) TBx and 70 (4.2%) LBx had an AKT1mut detected; and 602 (10.4%) TBx and 41 (2.5%) LBx had a PTEN alteration (mut or loss) detected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We observed that the prevalence of an alteration in the PI3K/AKT pathway in TBx collected in 1st, 2nd, and 3rd lines of therapy was 55.1% (n = 1,186/2,154), 48.3% (n = 130/269), and 54.6% (n = 118/216), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with TBx in 1st (n = 2154), 2nd (n = 269), and 3rd (n = 216) lines, both ESR1mut and a PI3K/AKT pathway GA were detected in 4.4% (95), 8.2% (22), and 17.1% (37), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Resistance to CDK4/6 inhibitors
“Some of the somatic alterations described above have also been shown to promote resistance to CDK4/6i, including FGFR1 amplification, PTEN alterations, and ERBB2 mutations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, RB1 and FAT1 alterations appear to be exclusively associated with resistance to CDK4/6 inhibitors and less to antiestrogens alone” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Acquired hotspot mutations in PIK3CA have been reported following progression on either fulvestrant alone or in combination with CDK4/6 inhibitors (CDK4/6i)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Estrogen receptor-independent growth and loss of estrogen receptor expression
“Loss of ER expression occurs in a minority (~10%) of endocrine-resistant breast cancers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition to ER, RTKs activate other transcription factors that promote ER-independent survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Indeed, Razavi et al. reported that 60% of endocrine-resistant MBC lacked known somatic drivers of resistance” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Estrogen receptor-dependent and estrogen receptor-independent routes of resistance
“Still, these may be thought of as either (1) reactivating ER signalling despite drug administration or (2) bypassing ER to drive another oncogenic programme” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Interestingly, resistance mechanisms relating to active ER signalling are more typically observed in tumours that manifest with a period of apparent sensitivity followed by resistance, that is, resistance that is acquired under the pressure of therapy, whereas ER-independent mechanisms often appear in tumours that are intrinsically resistant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pink and red: other cancers lose dependency on ER altogether.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote